| Not Yet Recruiting | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded t NCT07437963 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma NCT07211737 | Baylor College of Medicine | Phase 1 |
| Recruiting | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287 | Beijing Biotech | Phase 1 / Phase 2 |
| Recruiting | Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Rel NCT07027748 | Steven DuBois, MD | Phase 1 |
| Recruiting | PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma NCT07007117 | Stephan Grupp MD PhD | Phase 1 |
| Recruiting | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors NCT06721689 | Theodore Laetsch | Phase 1 / Phase 2 |
| Recruiting | Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma NCT06803875 | Roberto Chiarle | Phase 1 / Phase 2 |
| Recruiting | Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or R NCT05400603 | Emory University | Phase 1 |
| Recruiting | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma NCT05650749 | Stephan Grupp MD PhD | Phase 1 |
| Recruiting | NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab NCT04211675 | Nationwide Children's Hospital | Phase 1 / Phase 2 |
| Suspended | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Youn NCT04539366 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or R NCT04751383 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You NCT04500548 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory NCT06438614 | Fundació Sant Joan de Déu | Phase 2 |
| Terminated | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tum NCT04530487 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapse NCT04023331 | Clarity Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With NCT03794349 | Children's Oncology Group | Phase 2 |
| Active Not Recruiting | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL NCT03635632 | Baylor College of Medicine | Phase 1 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02095132 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recu NCT01711554 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma NCT01109238 | Giselle Sholler | — |
| Completed | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770 | Children's Oncology Group | Phase 1 / Phase 2 |